As of 2024-12-12, the EV/EBITDA ratio of Immunitybio Inc (IBRX) is -10.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IBRX's latest enterprise value is 4,096.26 mil USD. IBRX's TTM EBITDA according to its financial statements is -405.27 mil USD. Dividing these 2 quantities gives us the above IBRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 16.5x | 15.0x |
| Forward P/E multiples | 15.0x - 17.7x | 15.8x |
| Fair Price | (6.78) - (7.34) | (6.90) |
| Upside | -315.2% - -333.0% | -319.1% |
| Date | EV/EBITDA |
| 2024-12-09 | -14.29 |
| 2024-12-06 | -14.69 |
| 2024-12-05 | -13.70 |
| 2024-12-04 | -14.13 |
| 2024-12-03 | -13.68 |
| 2024-12-02 | -14.72 |
| 2024-11-29 | -14.89 |
| 2024-11-27 | -15.05 |
| 2024-11-26 | -15.10 |
| 2024-11-25 | -14.89 |
| 2024-11-22 | -15.05 |
| 2024-11-21 | -14.88 |
| 2024-11-20 | -14.48 |
| 2024-11-19 | -15.68 |
| 2024-11-18 | -14.82 |
| 2024-11-15 | -13.50 |
| 2024-11-14 | -14.46 |
| 2024-11-13 | -14.36 |
| 2024-11-12 | -14.67 |
| 2024-11-11 | -15.93 |
| 2024-11-08 | -16.24 |
| 2024-11-07 | -15.55 |
| 2024-11-06 | -15.86 |
| 2024-11-05 | -15.91 |
| 2024-11-04 | -15.30 |
| 2024-11-01 | -15.50 |
| 2024-10-31 | -15.33 |
| 2024-10-30 | -16.41 |
| 2024-10-29 | -16.34 |
| 2024-10-28 | -17.76 |
| 2024-10-25 | -15.60 |
| 2024-10-24 | -12.79 |
| 2024-10-23 | -10.89 |
| 2024-10-22 | -10.97 |
| 2024-10-21 | -11.12 |
| 2024-10-18 | -11.12 |
| 2024-10-17 | -10.84 |
| 2024-10-16 | -11.53 |
| 2024-10-15 | -11.50 |
| 2024-10-14 | -11.55 |
| 2024-10-11 | -11.37 |
| 2024-10-10 | -10.31 |
| 2024-10-09 | -10.54 |
| 2024-10-08 | -11.04 |
| 2024-10-07 | -10.97 |
| 2024-10-04 | -10.82 |
| 2024-10-03 | -10.74 |
| 2024-10-02 | -11.17 |
| 2024-10-01 | -11.25 |
| 2024-09-30 | -11.55 |